2020年度

1. RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis.

Tsuru S, Ito Y, Matsuda H, Hosono K, Inoue T, Nakamoto S, Kurashige C, Mishima T, Tsujikawa K, Okamoto H, Majima M.

Lab Invest. 2020 May;100(5):738-750.

2. MicroRNA-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma.

Wang C, Uemura M, Tomiyama E, Matsushita M, Koh Y, Nakano K, Hayashi Y, Ishizuya Y, Jingushi K, Kato T, Hatano K, Kawashima A, Ujike T, Nagahara A, Fujita K, Imamura R, Tsujikawa K, Nonomura N.

Cancer Sci. 2020 Apr;111(4):1146-1155.

3. Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer.

Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K.

Oncol Rep. 2021 Jan;45(1):309-316.

4. The CGRP receptor component RAMP1 links sensory innervation with YAP activity in the regenerating liver.

Laschinger M, Wang Y, Holzmann G, Wang B, Stöß C, Lu M, Brugger M, Schneider A, Knolle P, Wohlleber D, Schulze S, Steiger K, Tsujikawa K, Altmayr F, Friess H, Hartmann D, Hüser N, Holzmann B.

FASEB J. 2020 Jun;34(6):8125-8138.

5. Inhibition of receptor activity-modifying protein 1 suppresses the development of endometriosis and the formation of blood and lymphatic vessels.

Honda M, Ito Y, Hattori K, Hosono K, Sekiguchi K, Tsujikawa K, Unno N, Majima M.

J Cell Mol Med. 2020 Oct;24(20):11984-11997.

6．大阪大学における新たな産学連携の取り組み

関西医薬品協会 会報 2月 第865号 41-46, 2021

辻川和丈